Company intelligence / Profile preview
BioNxt Solutions Inc.
- Ownership
- Private
- Development stage
- Preclinical
Overview
BioNxt Solutions specializes in next-generation drug delivery technologies with a focus on neurodegenerative and autoimmune diseases. The company’s lead program involves a human bioequivalence study for multiple sclerosis using advanced transdermal or sublingual formulations. Other pipeline assets are in preclinical development targeting immune and neurological disorders. The company also has rapid diagnostic products under evaluation in Europe and an active program developing psychedelic medicines.[1][5][10]
- Therapeutic areas
- RheumatologyImmunologyEndocrinologyOtherNeurology
- Modalities
- Small molecules[8]Synthetic peptides[8]Chemical drugs[8]Transdermal patches (drug delivery)[1][2][6]Oral dissolvable films (ODF/sublingual)[2][6]Enteric-coated tablets (oral drug delivery)[6]
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on BioNxt Solutions Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioNxt Solutions Inc..